These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17021811)

  • 21. Discontinuing antithyroid drug therapy before ablation with radioiodine in Graves disease.
    Burch HB; Solomon BL; Wartofsky L; Burman KD
    Ann Intern Med; 1994 Oct; 121(8):553-9. PubMed ID: 7521992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
    Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
    Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Concept and validation of a simple model of the intrathyroidal iodine kinetics].
    Rink T; Bormuth FJ; Braun S; Zimny M; Schroth HJ
    Nuklearmedizin; 2004 Feb; 43(1):21-5. PubMed ID: 14978537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of Graves' disease: results of a prospective study.
    Eschmann SM; Thelen MH; Dittmann H; Bares R
    Exp Clin Endocrinol Diabetes; 2006 May; 114(5):222-6. PubMed ID: 16804795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
    Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
    Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro-deoxyglucose positron emission tomography.
    Boerner AR; Voth E; Theissen P; Wienhard K; Wagner R; Schicha H
    Thyroid; 1998 Sep; 8(9):765-72. PubMed ID: 9777746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of methimazole on thyroid uptake of pertechnetate and radioiodine in normal cats.
    Nieckarz JA; Daniel GB
    Vet Radiol Ultrasound; 2001; 42(5):448-57. PubMed ID: 11678569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Follow-up comparison of short-term versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves' disease.
    Bouma DJ; Kammer H; Greer MA
    J Clin Endocrinol Metab; 1982 Dec; 55(6):1138-42. PubMed ID: 6182155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Serum thyroxine and triiodothyronine levels after a single dose and after 2-month-long thiamazole treatment of Graves' disease with reference to drug's pharmacokinetics].
    Syrenicz A
    Ann Acad Med Stetin; 1990; 36():133-52. PubMed ID: 2099104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication.
    Sabri O; Zimny M; Schulz G; Schreckenberger M; Reinartz P; Willmes K; Buell U
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1229-33. PubMed ID: 10199759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
    Andrade VA; Gross JL; Maia AL
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
    Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
    Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
    Alexander EK; Larsen PR
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of antithyroid medication and radioiodine therapy in pediatric Graves' disease.
    Leu SW; Chi CS; Shu SG
    Acta Paediatr Taiwan; 2003; 44(4):220-6. PubMed ID: 14674226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
    Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
    J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of prior carbimazole on the outcome of radioiodine therapy in pediatric and adolescent Graves' disease.
    Ballal S; Soundararajan R; Singh H; Garg A; Chopra S; Bal C
    Nucl Med Commun; 2015 Jun; 36(6):566-72. PubMed ID: 25757198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease.
    Van Isselt JW; de Klerk JM; Koppeschaar HP; Van Rijk PP
    Nucl Med Commun; 2000 Jul; 21(7):609-16. PubMed ID: 10994662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.